of patients studied. Both patients' serum and immunoglobulins induced platelet clumping in normal samples anticoagulated with EDTA (indirect test). This was prevented by incubation ofblood samples at 37°C and almost completely inhibited by the platelet inhibitors ASA, PGE1, and apyrase. Pseudothrombocytopenia was also entirely prevented by an antigen to gpIlb-Ma monoclonal antibody that recognises fibrinogen and the von Willebrand factor binding site. Pseudothrombocytopenia was almost completely abolished after the addition of RGD peptide, the recognition sequence of cytoadhesive proteins. Conclusions-These findings suggest that EDTA dependent pseudothrombocytopenia is caused by agglutinating antibodies that recognise cytoadhesive receptors on platelet gpllb-Ma and that an efficient platelet metabolism is required. (7 Clin Pathol 1994; 47:625-630) Pseudothrombocytopenia is the result of a spuriously low platelet count induced by agglutinating antibodies that cause in vitro platelet clumping.l4 The condition is seen most often in blood samples anticoagulated with EDTA, although citrate, oxalate, or heparin have also been implicated."7 Most of the agglutinins react most strongly at room temperature or below, but some are temperature independent or react best at 370C.8 Most are IgG, but IgM, IgA, and combinations of IgG and IgM or IgG and IgA also have been described.6 91 That platelet glycoprotein (gp) IIb-IIIa is involved in the EDTA induced antibody reaction was suggested by the observation that platelets from patients with Glanzmann's disease do not react with these antibodies. 9 Identification of cold antibody (IgM) directed against platelet gpIlb6 that causes pseudothrombocytopenia is further support for this hypothesis. No abnormalities of platelet function have been described in association with EDTA dependent pseudothrombocytopenia.
Methods
Thirty three patients with EDTA dependent pseudothrombocytopenia were studied: eight men (mean (SEM) age 41-1 (162) years) and 25 women (mean (SEM) age 43.9 years). Most (18 of 33) were healthy at the time of presentation. In the others, pseudothrombocytopenia was associated with various diseases (table) .
The samples for platelet count were drawn from the antecubital vein, using 10 mM EDTA, 0-38% sodium citrate, 10 IU heparin or 1 % ammonium oxalate using the Unopette system (Becton Dickinson, USA) as anticoagulants.12 Platelet counts were performed after two hours of incubation at 22°C. Only individual platelets were counted. Platelet counts and the presence of platelet aggregates were determined by phase contrast microscopy. For each sample, counting was performed blind at least three times. Differences between the counts were always below 10%. The size of platelet aggregates was expressed as the number of platelets involved.
In a direct test platelet counts were obtained for patients' blood samples. Indirect tests or mixing experiments were carried out by adding one part of the patient's serum or purified immunoglobulins to one part of normal blood. The platelet counts were performed after two hours of incubation at 22GC.
Monoclonal antibodies and inhibitors of platelet function (ASA, PGE1, and apyrase) were included into the anticoagulants for blood collection in the direct tests. In the indirect experiments monoclonal antibodies and antiplatelet drugs were added to normal blood samples. After 22°C patients' sera or immunoglobulins were added and platelets were counted two hours later. In the indirect tests goat anti-human immunoglobulins were also used. Serum or ammonium precipitate (100 pul) was incubated with 25 pul of anti-human IgG (2-3 mg/ml) or anti-human IgM (1-075 mg/ml) or anti-IgA (2-5 mg/ml) (final concentration) for 10 minutes at 22°C, without stirring. Then 100 pl of EDTA blood sample was added and platelet number was measured two hours later. An anti HLA-DL monoclonal antibody (B 33 3) was used as the control in one experiment.
The bleeding time was measured using a Simplate II bleeding time device (General Diagnostic, Morris Plains, New Jersey, USA).
Immunoglobulins were purified by initial precipitation of patients' sera with 40% ammonium sulphate. The precipitate was then centrifuged at 10 000 x g for 20 minutes dissolved in phosphate buffered saline (PBS) and dialysed against PBS overnight and applied to protein-G sepharose (Pharmacia, Sweden) to separate the IgG fraction. The concentration of IgG fraction, diluted in PBS buffer, ranged from 1246 mg% to 1800 mg%.
Monoclonal antibodies against platelet gpIb-IX (LJIB 1) and antigen to gpIIb-IIIa complex (LJCP8) were prepared and characterised, as described elsewhere.13 14 LJIB1 recognises the von Willebrand factor binding site and completely inhibits ristocetin induced platelet aggregation. LJCP8 recognises fibrinogen, von Willebrand factor and the fibronectin binding site. In the experiments using blood from the patient with afibrinogenaemia, 1 volume of EDTA afibrinogenaemic blood was added to 1 tors. In the direct tests platelet clu partially prevented by the addition ASA, lower concentrations having
The formation of platelet aggregat partially inhibited by 42-3 mM 10 IU/ml apyrase (fig 2A) . In the iI on the contrary, platelet clun completely inhibited by ASA PGEI (21-2 mM), and apyrase ( fig 2B) .
A dose response association wa for ASA (fig 3) : there was almos prevention of platelet clumping wil 5 mg/ml ASA, but lower concentra lesser effect. It should be noted thE concentration of ASA was reduce RGD (mM) 25 dard deviation increased, due to differences between the patients, in the minimal dose of Y-ASA required to prevent the pseudothrombocytopenia phenomenon. ASA was also administered in vivo (600 mg daily for a week) in four patients. In vivo the drug did not affect the development of pseudothrombocytopenia. Similarly, when ASA (600 mg daily) was administered in vivo to the donor for the indirect test, platelet clumping was not prevented in vitro.
To clarify the role of platelet receptor/s, antigens to platelet gpIb-IX (LJIB1, 100 mg/ml) and gpIlb-IIIa (LJCP8, 330 ,ug/ml) monoclonal antibodies were used. LJIB1, which recognises the von Willebrand factor binding site on gpIb-IX, did not change either the platelet count or the presence of platelet aggregates (fig 4) . In contrast, LJCP8, which recognises the von Willebrand factor and fibrinogen binding site on gpIIb-IIIa, completely 80 320 inhibited pseudothrombocytopenia and the effect was dose-dependent ( fig 5) . A maximal effect was observed with monoclonal antibody concentrations between 330 ,ug/ml and unping was 165 ,ug/ml, with a rapid decrease between 1 of mg/mL 80 ug/ml and 5,ug/ml. Similar results were g no effect. obtained in both the direct and indirect experLes was also iments. The specificity of LJCP8 in the pre-PGE1 and vention of platelet clumping was tested with adirect test, Arg-Gly-Asp (RGD) peptide. As shown in fig nping was 6, when patients' blood samples were incu-(2 mg/ml), bated with increasing concentrations of RGD (10 IU/ml) peptide, there was the platelet count progressively increased. Platelet clumping was comis observed pletely inhibited by 5 mM RGD, while there ;t complete was a rapid reduction in the effects at doses th 1, 2, and ranging between 2-5 and 1 mM. Lower conLtions had a centrations had no effect. The dose-response at when the relation of LJCP8 inhibition, resembling a sigd the stan-moid curve, was similar to that observed for RGD peptide. The contribution of soluble fibrinogen was explored in the indirect test, with EDTA anticoagulated blood from a patient with afibrinogenaemia (fibrinogen below 20 mg%). After the addition of the patient's serum the decrease in platelet count observed in the afibrinogenaemic blood sample was similar to those in normal blood (58 x 109/l v 46 x 109/1 compared with 119 x 109/l and 132 x 109/l, respectively, using citrated samples).
Discussion
EDTA dependent pseudothrombocytopenia consists of spuriously low platelet counts caused by the presence of platelet agglutinating antibodies that induce "in vitro" platelet clumping when the blood samples have been collected in EDTA.
We have shown, in this study, that the platelet site to which EDTA dependent agglutinins bind is the adhesive receptor on gpIIbIIIa, and that normal platelet function seems to be required for the occurrence of platelet clumping. Platelet gpIlb-Illa, a member of the integrin family,'718 has a crucial role in haemostasis by binding fibrinogen and von Willebrand factor during the formation of the platelet plug.'9 gpIIb-IIIa is a Ca + + dependent heterodimer. Removal of calcium by chelation causes loss of gpIIb-IIIa receptor function, and, at temperatures above 25°C, dissolution of the gpIIb-IIIa complex into its individual subunits. 20 The binding of Ca+ + by EDTA also affects the formation of the gpIIb-IIIa complex.7 We surmise that under our experimental conditions EDTA caused a change in the formation of the gpIIb-IIIa complex into some epitope/s available to platelet agglutinating antibodies.
The dissociation of the complex, after incubation of platelets with 5 mM EDTA at 370C, strongly diminished the expression of this epitope and prevented the development of pseudothrombocytopenia.
The epitope to which agglutinins bind seems to be related to the LJCP8 monoclonal antibody, which is directed against the cytoadhesive receptor for gpIIb-IIIa of stimulated and unstimulated platelets. '4 In all the patients studied LJCP8 prevented platelet clumping in a dose dependent and saturable manner. That this effect is specific seems to be confirmed by the finding that pseudothrombocytopenia was also prevented by the RGD peptide, which is the recognition sequence for adhesive proteins.2' The doseresponse association with the RGD peptide was similar to that seen with LJCP8. This seems to suggest that both events are the consequence of occupation of the same site. Furthermore, the sigmoid nature of the kinetics for both suggests cooperation of the mechanisms responsible for the inhibition of pseudothrombocytopenia.
Soluble fibrinogen does not seem to be necessary, because platelet clumping can be induced in blood from an afibrinogenaemic patient by the patient's agglutinins.22 On the other hand, platelet clumping seems to require normal platelet metabolism, as inhibitors of platelet activation, such as ASA, PGE1, and apyrase, prevent the phenomenon. This was incomplete in the direct experiment. In contrast, there was almost complete inhibition of pseudothrombocytopenia in the indirect test. These differences may be the result of the method of sample processing: in the indirect test platelets were incubated with the inhibitors prior to the addition of patients' agglutinins; in the direct test this was done afterwards. Furthermore, the inhibition of platelet clumping became evident only at doses significantly higher than those which normally inhibit platelet function. This could explain the failure of ASA administered in vivo to modify pseudothrombocytopenia. The requirement for normal platelet metabolism seems to suggest that the EDTA dependent clumping is an aggregation rather than an agglutination phenomenon. But in contrast to classic platelet aggregation, which requires binding of fibrinogen to the cytoadhesive receptor of gpIlb-IIIa,2' soluble fibrinogen does not seem to be required for the development of pseudothrombocytopenia.
The pathophysiology of antibody production is unknown and the various diseases found in some of the patients studied do not offer any clues. As in other reported studies,24 most of our patients were female, and most of them healthy at the time of presentation.2526
The diseases present were heterogeneous27-29 and not associated with autoimmune or clinically evident neoplastic pathology. 30 In conclusion, our findings suggest that the cytoadhesive receptor on gpIlb-IIIa has a role in EDTA dependent pseudothrombocytopenia, which also seems to require normal platelet metabolism. An epitope which normally participates in platelet function becomes available after an EDTA dependent conformational change of gpIIb-IIIa and mediates an aggregation phenomenon that does not seem to require the fibrinogen molecule.
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